Although subsequent studies have reported NRG1 fusions at low frequencies in various tumor types, NSCLC still exhibits the highest number of cases, and currently, there are no approved targeted therapies specifically designed for NRG1 fusion-positive lung cancers (22–26). Here, NRG1 is linked to lung carcinoma.